TOXICITY AND EFFICACY OF LOMUSTINE PLUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS

被引：0
|
作者：
Jakobsen, Jan Nyrop [1 ]
Urup, Thomas [1 ]
Grunnet, Kirsten [1 ,2 ]
Christensen, Ib Jarle [3 ]
Villingshoj, Mette [2 ]
Poulsen, Hans Skovgaard [1 ,2 ]
机构：
[1] Rigshosp, Dept Oncol, Copenhagen, Denmark
[2] Rigshosp, Dept Radiat Biol, Copenhagen, Denmark
[3] Univ Copenhagen, Hvidovre Hosp, Lab Gastroenterol, Copenhagen, Denmark
来源：
NEURO-ONCOLOGY | 2017年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ACTR-26
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [31] Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine
    Heiland, D. H.
    Masalha, W.
    Franco, P.
    Machein, M. R.
    Weyerbrock, A.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2016, 126 (03) : 567 - 575
  • [32] Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
    Beije, N.
    Kraan, J.
    Taal, W.
    van der Holt, B.
    Oosterkamp, H. M.
    Walenkamp, A. M.
    Beerepoot, L.
    Hanse, M.
    van Linde, M. E.
    Otten, A.
    Vernhout, R. M.
    de Vos, F. Y. F.
    Gratama, J. W.
    Sleijfer, S.
    van den Bent, M. J.
    [J]. BRITISH JOURNAL OF CANCER, 2015, 113 (02) : 226 - 231
  • [33] Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
    N Beije
    J Kraan
    W Taal
    B van der Holt
    H M Oosterkamp
    A M Walenkamp
    L Beerepoot
    M Hanse
    M E van Linde
    A Otten
    R M Vernhout
    F Y F de Vos
    J W Gratama
    S Sleijfer
    M J van den Bent
    [J]. British Journal of Cancer, 2015, 113 : 226 - 231
  • [34] SAFETY AND EFFICACY OF BEVACIZUMAB PLUS TTFIELDS IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM): DATA FROM A PHASE II CLINICAL TRIAL
    Fallah, Jaleh
    Chaudhary, Rekha
    Rogers, Lisa
    Wei, Wei
    Brewer, Cathy
    Peereboom, David
    Ahluwalia, Manmeet
    [J]. NEURO-ONCOLOGY, 2019, 21 : 18 - 18
  • [35] SAFETY AND EFFICACY OF BEVACIZUMAB AND ERLOTINIB FOR RECURRENT GLIOBLASTOMA PATIENTS IN A PHASE II STUDY
    Sathornsumetee, Sith
    Desjardins, Annick
    Vredenburgh, James
    Rich, Jeremy
    Gururangan, Sridharan
    Friedman, Allan
    Friedman, Henry
    Reardon, David
    [J]. NEURO-ONCOLOGY, 2008, 10 (05) : 827 - 827
  • [36] Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
    Capper, David
    von Deimling, Andreas
    Brandes, Alba A.
    Carpentier, Antoine F.
    Kesari, Santosh
    Sepulveda-Sanchez, Juan M.
    Wheeler, Helen R.
    Chinot, Olivier
    Cher, Lawrence
    Steinbach, Joachim P.
    Specenier, Pol
    Rodon, Jordi
    Cleverly, Ann
    Smith, Claire
    Gueorguieva, Ivelina
    Miles, Colin
    Guba, Susan C.
    Desaiah, Durisala
    Estrem, Shawn T.
    Lahn, Michael M.
    Wick, Wolfgang
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (05)
  • [37] Dose-dependent efficacy of bevacizumab in recurrent glioblastoma
    Melhem, Jawad M.
    Tahir, Ali
    Calabrese, Eirena
    Granovskaya, Inga
    Atenafu, Eshetu G.
    Sahgal, Arjun
    Lim-Fat, Mary Jane
    Perry, James R.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2023, 161 (03) : 633 - 641
  • [38] A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENTIN RECURRENT GLIOBLA STOMA: THE DUTCH BELOB STUDY
    Taal, Walter
    Oosterkamp, H.
    Walenkamp, Annemieke
    Beerenpoot, Lucas
    Hanse, Monique
    Buter, Jan
    Honkoop, Aafke
    Boerman, Dolf
    de Vos, Filip
    Jansen, R.
    van der Berkmortel, Franchette
    Brandsma, Dieta
    Enting, Roelien
    Kros, Johan
    Bromberg, Jacoline
    van Heuvel, Irene
    Smits, Marion
    van der Holt, Ronnie
    Vernhout, Rene
    van den Bent, Martin
    [J]. NEURO-ONCOLOGY, 2013, 15 : 83 - 84
  • [39] Safety and efficacy of bevacizumab biosimilar in recurrent/progressive glioblastoma
    Kumar, Gunjesh
    DSouza, Hollis
    Menon, Nandini
    Srinivas, Sujay
    Vallathol, Dilip Harindran
    Boppana, Mounika
    Rajpurohit, Annu
    Mahajan, Abhishek
    Janu, Amit
    Chatterjee, Abhishek
    Krishnatry, Rahul
    Gupta, Tejpal
    Jalali, Rakesh
    Patil, Vijay M.
    [J]. ECANCERMEDICALSCIENCE, 2021, 15
  • [40] Dose-dependent efficacy of bevacizumab in recurrent glioblastoma
    Jawad M. Melhem
    Ali Tahir
    Eirena Calabrese
    Inga Granovskaya
    Eshetu G. Atenafu
    Arjun Sahgal
    Mary Jane Lim-Fat
    James R. Perry
    [J]. Journal of Neuro-Oncology, 2023, 161 : 633 - 641
12345